Drugs / SKY-0515
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07537075 | Apr 2026 → Dec 2029 expected | Huntington disease | Skyhawk Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT07378644 Comparator | Jan 2026 → Dec 2028 expected | Huntington disease | Skyhawk Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06873334 Comparator | May 2025 → May 2027 expected | Huntington disease | Skyhawk Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKY-0515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07537075 ↗ |
| Action | Inhibit | “SKY-0515 is designed to reduce mHTT protein levels by lowering of HTT messenger RNA (mRNA) through a splicing mechanism” NCT06873334 ↗ |
| Modality | Small molecule | “novel, orally-administered small molecule mRNA-splicing modulator” NCT06873334 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT06873334 ↗ |
| Target | HTT | “SKY-0515 is designed to reduce mHTT protein levels by lowering of HTT messenger RNA (mRNA) through a splicing mechanism” NCT06873334 ↗ |
| Target | PMS1 | “Additionally, the drug lowers postmeiotic segregation 1 (PMS1) protein” NCT06873334 ↗ |